Boston Family Office LLC Sells 2,175 Shares of Novo Nordisk A/S $NVO

Boston Family Office LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 5.7% during the second quarter, HoldingsChannel reports. The firm owned 35,673 shares of the company’s stock after selling 2,175 shares during the quarter. Boston Family Office LLC’s holdings in Novo Nordisk A/S were worth $2,462,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Lockheed Martin Investment Management Co. boosted its holdings in Novo Nordisk A/S by 179.4% in the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock valued at $2,999,000 after purchasing an additional 27,900 shares during the period. Unified Investment Management bought a new position in shares of Novo Nordisk A/S during the 2nd quarter worth about $692,000. Acadian Asset Management LLC raised its position in shares of Novo Nordisk A/S by 15,919.9% during the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock valued at $72,523,000 after buying an additional 1,038,137 shares during the last quarter. Guild Investment Management Inc. lifted its stake in shares of Novo Nordisk A/S by 20.7% in the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after buying an additional 6,345 shares during the period. Finally, Norden Group LLC lifted its stake in shares of Novo Nordisk A/S by 216.3% in the second quarter. Norden Group LLC now owns 96,332 shares of the company’s stock valued at $6,649,000 after buying an additional 65,877 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the topic of several research reports. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, The Goldman Sachs Group decreased their price target on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $56.83.

Novo Nordisk A/S Stock Up 1.3%

Shares of NYSE NVO opened at $49.35 on Monday. The stock has a market cap of $220.33 billion, a PE ratio of 13.56, a PEG ratio of 2.33 and a beta of 0.65. The business has a fifty day moving average of $52.81 and a two-hundred day moving average of $59.66. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $112.52. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.